Meet Emily Nault, Invert’s New SVP of Commercial

Invert is excited to announce that Emily Nault has joined the company as our Senior Vice President of Commercial.
Emily brings over two decades of valuable experience in strategic sales for the life sciences. With a background in bioprocess and supply chain management, she has a deep understanding of the technical solutions needed to address the industry’s most persistent challenges.
Before joining Invert, Emily served as Senior Vice President of Platform Sales and Commerce at life sciences procurement platform LabViva, where she led commercial strategy. She held director-level positions at Aldevron, Cytiva, and Sartorius, overseeing global sales strategy, e-commerce, and management of key accounts in bioprocess.
Her collective experience informs a grounded knowledge of biomanufacturing market needs, with her earlier roles at Sartorius and Genzyme giving her insight into bioprocess technical sales as well as marketing and purchasing trends.
"I’ve spent my career helping biopharma teams overcome operational and data challenges—and I’ve also been a customer in biotech, so I know the pain points firsthand,” says Emily.
“What drew me to Invert was the clarity of its mission and the strength of its platform. There’s a real opportunity to change how process development is done, and I’m excited to help more companies realize that potential.”
Emily’s experience lies within the intersection of bioprocess and digital transformation—exactly where Invert focuses on advancing data infrastructure and decision-making. Her combination of technical knowledge, deep industry connections, and business acumen will help Invert expand the value it delivers to customers.
Invert believes that Emily is an instrumental addition to leadership, and is confident that her expertise will be an invaluable resource to expand the company’s presence in the biopharmaceutical industry.

Why ELNs and LIMS are not enough for PD teams
One of the questions we’re asked frequently is whether Invert is an ELN or LIMS—our answer is that Invert captures both systems’ strengths and fixes their weaknesses. We’ll discuss the trade-offs and shortcomings of ELN and LIMS when it comes to bioprocess data to explain how.
Read More ↗.png)
How Invert uses meta-learning to leverage old bioprocess data
With meta-learning techniques, Invert’s ML team was able to reduce new data needs by as much as 90% by leveraging old data from different, but loosely related, bioprocess programs.
Read More ↗.png)
Pioneers in Bioprocessing: Q&A with Biopharma Executive, Steven Lang, Ph.D.
Biotech and synthetic biology companies have much to do. Handling everything in-house—from strain design to process development—can stretch funding and resources thin.
Read More ↗